{"doi":"10.1016/j.aca.2021.339023","title":"In-depth triacylglycerol profiling using MS3 Q-Trap mass spectrometry","abstract":"Total triacylglycerol (TAG) level is a key clinical marker of metabolic and cardiovascular diseases. However, the roles of individual TAGs have not been thoroughly explored in part due to their extreme structural complexity. We present a targeted mass spectrometry-based method combining multiple reaction monitoring (MRM) and multiple stage mass spectrometry (MS3) for the comprehensive qualitative and semiquantitative profiling of TAGs. This method referred as TriP-MS3 – triacylglycerol profiling using MS3 – screens for more than 6,700 TAG species in a fully automated fashion. TriP-MS3 demonstrated excellent reproducibility (median interday CV ∼ 0.15) and linearity (median R2 = 0.978) and detected 285 individual TAG species in human plasma. The semiquantitative accuracy of the method was validated by comparison with a state-of-the-art reverse phase liquid chromatography (RPLC)-MS (R2 = 0.83), which is the most commonly used approach for TAGs profiling. Finally, we demonstrate the utility and the versatility of the method by characterizing the effects of a fatty acid desaturase inhibitor on TAG profiles in vitro and by profiling TAGs in Caenorhabditis elegans.","journal":"Analytica Chimica Acta","year":2021,"id":180569,"datarank":0.4335557636844247,"base_score":2.8903717578961645,"endowment":2.8903717578961645,"self_citation_contribution":0.4335557636844247,"citation_network_contribution":0.0,"self_endowment_contribution":0.4335557636844247,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":17,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9573,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":329567,"name":"Josefina Priotti","orcid":"0000-0001-7493-3047","position":1,"is_corresponding":false},{"id":331841,"name":"Pablo Domizi","orcid":"0000-0003-2903-0337","position":2,"is_corresponding":false},{"id":729888,"name":"Katharina Papsdorf","orcid":"0000-0001-9873-7585","position":3,"is_corresponding":false},{"id":329570,"name":"Deanna L. Kroetz","orcid":"0000-0001-5997-270X","position":4,"is_corresponding":false},{"id":14927,"name":"Anne Brunet","orcid":"0000-0002-4608-6845","position":5,"is_corresponding":false},{"id":17260,"name":"Kévin Contrepois","orcid":"0000-0001-9678-5161","position":6,"is_corresponding":false},{"id":5648,"name":"Michael P. Snyder","orcid":"0000-0003-0784-7987","position":7,"is_corresponding":false},{"id":519169,"name":"Matías Cabruja","orcid":"0000-0001-7691-6494","position":0,"is_corresponding":true}],"reference_count":41,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-18T23:47:57.268805Z","pmid":"34625255","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}